APO Research
Talk to an analyst

APO RESEARCH · REPORT

Chemotherapy Induced Peripheral Neuropathy Treatment

CIPN is a common adverse effect of several cancer therapies including taxanes and platinum drugs. Symptoms include decreased sensation and tingling of the hands and feet, severe pain, numbness and muscle weakness, all of which can occur during cancer treatment, and frequently persist after chemotherapy has ended.

Explore the product
View pricing & licenses

Product & engineering

Understand the product.

CIPN is a common adverse effect of several cancer therapies including taxanes and platinum drugs. Symptoms include decreased sensation and tingling of the hands and feet, severe pain, numbness and muscle weakness, all of which can occur during cancer treatment, and frequently persist after chemotherapy has ended.

There are no approved therapies to combat the debilitating symptoms of CIPN now. Current alternatives include Palliative care using antidepressants, antiepileptic drugs, or opioids, all of which have well known adverse side effects.

Selected research

Market Outlook & Growth Opportunities

Global Chemotherapy Induced Peripheral Neuropathy Treatment Market Outlook and Growth Opportunities 2026

22 December 2025191 pages

Choose your research edition.

Industry ResearchChemotherapy Induced Peripheral Neuropathy Treatment Industry Research Report 2026124 pages · $2,950 USDIndustry Growth & TrendsGlobal Chemotherapy Induced Peripheral Neuropathy Treatment Industry Growth and Trends Forecast to 2032102 pages · $3,450 USDMarket StructureGlobal Chemotherapy Induced Peripheral Neuropathy Treatment Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032190 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Chemotherapy Induced Peripheral Neuropathy Treatment Market Outlook and Growth Opportunities 2026191 pages · $4,250 USDMarket Analysis & ForecastGlobal Chemotherapy Induced Peripheral Neuropathy Treatment Market Analysis and Forecast 2026-2032195 pages · $4,950 USD

Market perspective

CIPN is a common adverse effect of several cancer therapies including taxanes and platinum drugs. Symptoms include decreased sensation and tingling of the hands and feet, severe pain, numbness and muscle weakness, all of which can occur during cancer treatment, and frequently persist after chemotherapy has ended.

There are no approved therapies to combat the debilitating symptoms of CIPN now. Current alternatives include Palliative care using antidepressants, antiepileptic drugs, or opioids, all of which have well known adverse side effects.

Americas is the largest market with about 47% market share. Europe is follower, accounting for about 27% market share.

Read the full market overview

The key players are Aptinyx Inc, Asahi Kasei Pharma Corp, Regenacy Pharmaceuticals, MAKScientific LLC, Metys Pharmaceuticals AG, Nemus Bioscience Inc, PledPharma, Sova Pharmaceuticals Inc, DermaXon LLC, Kineta Inc, Krenitsky Pharmaceuticals Inc, PeriphaGen, Apexian Pharma, WinSanTor etc.

This report provides an overview of the global Chemotherapy Induced Peripheral Neuropathy Treatment market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Chemotherapy Induced Peripheral Neuropathy Treatment and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Chemotherapy Induced Peripheral Neuropathy Treatment sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Chemotherapy Induced Peripheral Neuropathy Treatment market size, projected growth trends, production technologies, key applications, and end-use industries.

Chemotherapy Induced Peripheral Neuropathy Treatment Segment by Company

Aptinyx Inc

Asahi Kasei Pharma Corp

Regenacy Pharmaceuticals

MAKScientific LLC

Metys Pharmaceuticals AG

Nemus Bioscience Inc

PledPharma

Sova Pharmaceuticals Inc

DermaXon LLC

Kineta Inc

Krenitsky Pharmaceuticals Inc

PeriphaGen

Apexian Pharma

WinSanTor

Chemotherapy Induced Peripheral Neuropathy Treatment Segment by Type

Calcium Channel α2-delta Ligands

Antidepressants

Opioids

Others

Chemotherapy Induced Peripheral Neuropathy Treatment Segment by Application

Platinum Agents

Taxanes

Vinca Alkaloids

Others

Chemotherapy Induced Peripheral Neuropathy Treatment Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global Chemotherapy Induced Peripheral Neuropathy Treatment status and future forecast, involving, sales, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions Chemotherapy Induced Peripheral Neuropathy Treatment market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Chemotherapy Induced Peripheral Neuropathy Treatment significant trends, drivers, influence factors in global and regions.

6. To analyze Chemotherapy Induced Peripheral Neuropathy Treatment competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Chemotherapy Induced Peripheral Neuropathy Treatment market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Chemotherapy Induced Peripheral Neuropathy Treatment and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Chemotherapy Induced Peripheral Neuropathy Treatment.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Chemotherapy Induced Peripheral Neuropathy Treatment market, including product definition, global market growth prospects, sales value, sales volume, and average price forecasts (2021-2032).

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Chemotherapy Induced Peripheral Neuropathy Treatment industry.

Chapter 3: Detailed analysis of Chemotherapy Induced Peripheral Neuropathy Treatment manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales and value of Chemotherapy Induced Peripheral Neuropathy Treatment in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.

Chapter 7: Sales and value of Chemotherapy Induced Peripheral Neuropathy Treatment in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Chemotherapy Induced Peripheral Neuropathy Treatment Industry Trends Table 2. Chemotherapy Induced Peripheral Neuropathy Treatment Industry Drivers Table 3. Chemotherapy Induced Peripheral Neuropathy Treatment Industry Opportunities and Challenges Table 4. Chemotherapy Induced Peripheral Neuropathy Treatment Industry Restraints Table 5. Global Chemotherapy Induced Peripheral Neuropathy Treatment Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Chemotherapy Induced Peripheral Neuropathy Treatment Revenue Share by Company (2021-2026) Table 7. Global Chemotherapy Induced Peripheral Neuropathy Treatment Sales Volume by Company (K Units) & (2021-2026) Table 8. Global Chemotherapy Induced Peripheral Neuropathy Treatment Sales Volume Share by Company (2021-2026) Table 9. Global Chemotherapy Induced Peripheral Neuropathy Treatment Average Price (US$/Unit) of Company (2021-2026) Table 10. Global Chemotherapy Induced Peripheral Neuropathy Treatment Company Ranking, (2024-2026) & (USD Million) Table 11. Global Chemotherapy Induced Peripheral Neuropathy Treatment Key Company Manufacturing Base & Headquarters Table 12. Global Chemotherapy Induced Peripheral Neuropathy Treatment Company, Product Type & Application Table 13. Global Chemotherapy Induced Peripheral Neuropathy Treatment Company Establishment Date Table 14. Global Company Market Concentration Ratio (CR5 and HHI) Table 15. Global Chemotherapy Induced Peripheral Neuropathy Treatment by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 16. Mergers & Acquisitions, Expansion Table 17. Significant Companies of Calcium Channel α2-delta Ligands Table 18. Significant Companies of Antidepressants Table 19. Significant Companies of Opioids Table 20. Significant Companies of Others Table 21. Global Chemotherapy Induced Peripheral Neuropathy Treatment Sales Volume by Type 2021 VS 2025 VS 2032 (K Units) Table 22. Global Chemotherapy Induced Peripheral Neuropathy Treatment Sales Volume by Type (2021-2026) & (K Units) Table 23. Global Chemotherapy Induced Peripheral Neuropathy Treatment Sales Volume by Type (2027-2032) & (K Units) Table 24. Global Chemotherapy Induced Peripheral Neuropathy Treatment Sales Volume Share by Type (2021-2026) Table 25. Global Chemotherapy Induced Peripheral Neuropathy Treatment Sales Volume Share by Type (2027-2032) Table 26. Global Chemotherapy Induced Peripheral Neuropathy Treatment Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 27. Global Chemotherapy Induced Peripheral Neuropathy Treatment Sales Value by Type (2021-2026) & (US$ Million) Table 28. Global Chemotherapy Induced Peripheral Neuropathy Treatment Sales Value by Type (2027-2032) & (US$ Million) Table 29. Global Chemotherapy Induced Peripheral Neuropathy Treatment Sales Value Share by Type (2021-2026) Table 30. Global Chemotherapy Induced Peripheral Neuropathy Treatment Sales Value Share by Type (2027-2032) Table 31. Significant Companies of Platinum Agents Table 32. Significant Companies of Taxanes Table 33. Significant Companies of Vinca Alkaloids Table 34. Significant Companies of Others Table 35. Global Chemotherapy Induced Peripheral Neuropathy Treatment Sales Volume by Application 2021 VS 2025 VS 2032 (K Units) Table 36. Global Chemotherapy Induced Peripheral Neuropathy Treatment Sales Volume by Application (2021-2026) & (K Units) Table 37. Global Chemotherapy Induced Peripheral Neuropathy Treatment Sales Volume by Application (2027-2032) & (K Units) Table 38. Global Chemotherapy Induced Peripheral Neuropathy Treatment Sales Volume Share by Application (2021-2026) Table 39. Global Chemotherapy Induced Peripheral Neuropathy Treatment Sales Volume Share by Application (2027-2032) Table 40. Global Chemotherapy Induced Peripheral Neuropathy Treatment Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 41. Global Chemotherapy Induced Peripheral Neuropathy Treatment Sales Value by Application (2021-2026) & (US$ Million) Table 42. Global Chemotherapy Induced Peripheral Neuropathy Treatment Sales Value by Application (2027-2032) & (US$ Million) Table 43. Global Chemotherapy Induced Peripheral Neuropathy Treatment Sales Value Share by Application (2021-2026) Table 44. Global Chemotherapy Induced Peripheral Neuropathy Treatment Sales Value Share by Application (2027-2032) Table 45. Global Chemotherapy Induced Peripheral Neuropathy Treatment Sales by Region: 2021 VS 2025 VS 2032 (K Units) Table 46. Global Chemotherapy Induced Peripheral Neuropathy Treatment Sales by Region (2021-2026) & (K Units) Table 47. Global Chemotherapy Induced Peripheral Neuropathy Treatment Sales Market Share by Region (2021-2026) Table 48. Global Chemotherapy Induced Peripheral Neuropathy Treatment Sales by Region (2027-2032) & (K Units) Table 49. Global Chemotherapy Induced Peripheral Neuropathy Treatment Sales Market Share by Region (2027-2032) Table 50. Global Chemotherapy Induced Peripheral Neuropathy Treatment Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 51. Global Chemotherapy Induced Peripheral Neuropathy Treatment Sales Value by Region (2021-2026) & (US$ Million) Table 52. Global Chemotherapy Induced Peripheral Neuropathy Treatment Sales Value Share by Region (2021-2026) Table 53. Global Chemotherapy Induced Peripheral Neuropathy Treatment Sales Value by Region (2027-2032) & (US$ Million) Table 54. Global Chemotherapy Induced Peripheral Neuropathy Treatment Sales Value Share by Region (2027-2032) Table 55. Global Chemotherapy Induced Peripheral Neuropathy Treatment Market Average Price (US$/Unit) by Region (2021-2026) Table 56. Global Chemotherapy Induced Peripheral Neuropathy Treatment Market Average Price (US$/Unit) by Region (2027-2032) Table 57. Global Chemotherapy Induced Peripheral Neuropathy Treatment Sales by Country: 2021 VS 2025 VS 2032 (K Units) Table 58. Global Chemotherapy Induced Peripheral Neuropathy Treatment Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 59. Global Chemotherapy Induced Peripheral Neuropathy Treatment Sales by Country (2021-2026) & (K Units) Table 60. Global Chemotherapy Induced Peripheral Neuropathy Treatment Sales Market Share by Country (2021-2026) Table 61. Global Chemotherapy Induced Peripheral Neuropathy Treatment Sales by Country (2027-2032) & (K Units) Table 62. Global Chemotherapy Induced Peripheral Neuropathy Treatment Sales Market Share by Country (2027-2032) Table 63. Global Chemotherapy Induced Peripheral Neuropathy Treatment Sales Value by Country (2021-2026) & (US$ Million) Table 64. Global Chemotherapy Induced Peripheral Neuropathy Treatment Sales Value Market Share by Country (2021-2026) Table 65. Global Chemotherapy Induced Peripheral Neuropathy Treatment Sales Value by Country (2027-2032) & (US$ Million) Table 66. Global Chemotherapy Induced Peripheral Neuropathy Treatment Sales Value Market Share by Country (2027-2032) Table 67. Aptinyx Inc Company Information Table 68. Aptinyx Inc Business Overview Table 69. Aptinyx Inc Chemotherapy Induced Peripheral Neuropathy Treatment Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 70. Aptinyx Inc Chemotherapy Induced Peripheral Neuropathy Treatment Product Portfolio Table 71. Aptinyx Inc Recent Development Table 72. Asahi Kasei Pharma Corp Company Information Table 73. Asahi Kasei Pharma Corp Business Overview Table 74. Asahi Kasei Pharma Corp Chemotherapy Induced Peripheral Neuropathy Treatment Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 75. Asahi Kasei Pharma Corp Chemotherapy Induced Peripheral Neuropathy Treatment Product Portfolio Table 76. Asahi Kasei Pharma Corp Recent Development Table 77. Regenacy Pharmaceuticals Company Information Table 78. Regenacy Pharmaceuticals Business Overview Table 79. Regenacy Pharmaceuticals Chemotherapy Induced Peripheral Neuropathy Treatment Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 80. Regenacy Pharmaceuticals Chemotherapy Induced Peripheral Neuropathy Treatment Product Portfolio Table 81. Regenacy Pharmaceuticals Recent Development Table 82. MAKScientific LLC Company Information Table 83. MAKScientific LLC Business Overview Table 84. MAKScientific LLC Chemotherapy Induced Peripheral Neuropathy Treatment Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 85. MAKScientific LLC Chemotherapy Induced Peripheral Neuropathy Treatment Product Portfolio Table 86. MAKScientific LLC Recent Development Table 87. Metys Pharmaceuticals AG Company Information Table 88. Metys Pharmaceuticals AG Business Overview Table 89. Metys Pharmaceuticals AG Chemotherapy Induced Peripheral Neuropathy Treatment Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 90. Metys Pharmaceuticals AG Chemotherapy Induced Peripheral Neuropathy Treatment Product Portfolio Table 91. Metys Pharmaceuticals AG Recent Development Table 92. Nemus Bioscience Inc Company Information Table 93. Nemus Bioscience Inc Business Overview Table 94. Nemus Bioscience Inc Chemotherapy Induced Peripheral Neuropathy Treatment Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 95. Nemus Bioscience Inc Chemotherapy Induced Peripheral Neuropathy Treatment Product Portfolio Table 96. Nemus Bioscience Inc Recent Development Table 97. PledPharma Company Information Table 98. PledPharma Business Overview Table 99. PledPharma Chemotherapy Induced Peripheral Neuropathy Treatment Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 100. PledPharma Chemotherapy Induced Peripheral Neuropathy Treatment Product Portfolio Table 101. PledPharma Recent Development Table 102. Sova Pharmaceuticals Inc Company Information Table 103. Sova Pharmaceuticals Inc Business Overview Table 104. Sova Pharmaceuticals Inc Chemotherapy Induced Peripheral Neuropathy Treatment Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 105. Sova Pharmaceuticals Inc Chemotherapy Induced Peripheral Neuropathy Treatment Product Portfolio Table 106. Sova Pharmaceuticals Inc Recent Development Table 107. DermaXon LLC Company Information Table 108. DermaXon LLC Business Overview Table 109. DermaXon LLC Chemotherapy Induced Peripheral Neuropathy Treatment Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 110. DermaXon LLC Chemotherapy Induced Peripheral Neuropathy Treatment Product Portfolio Table 111. DermaXon LLC Recent Development Table 112. Kineta Inc Company Information Table 113. Kineta Inc Business Overview Table 114. Kineta Inc Chemotherapy Induced Peripheral Neuropathy Treatment Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 115. Kineta Inc Chemotherapy Induced Peripheral Neuropathy Treatment Product Portfolio Table 116. Kineta Inc Recent Development Table 117. Krenitsky Pharmaceuticals Inc Company Information Table 118. Krenitsky Pharmaceuticals Inc Business Overview Table 119. Krenitsky Pharmaceuticals Inc Chemotherapy Induced Peripheral Neuropathy Treatment Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 120. Krenitsky Pharmaceuticals Inc Chemotherapy Induced Peripheral Neuropathy Treatment Product Portfolio Table 121. Krenitsky Pharmaceuticals Inc Recent Development Table 122. PeriphaGen Company Information Table 123. PeriphaGen Business Overview Table 124. PeriphaGen Chemotherapy Induced Peripheral Neuropathy Treatment Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 125. PeriphaGen Chemotherapy Induced Peripheral Neuropathy Treatment Product Portfolio Table 126. PeriphaGen Recent Development Table 127. Apexian Pharma Company Information Table 128. Apexian Pharma Business Overview Table 129. Apexian Pharma Chemotherapy Induced Peripheral Neuropathy Treatment Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 130. Apexian Pharma Chemotherapy Induced Peripheral Neuropathy Treatment Product Portfolio Table 131. Apexian Pharma Recent Development Table 132. WinSanTor Company Information Table 133. WinSanTor Business Overview Table 134. WinSanTor Chemotherapy Induced Peripheral Neuropathy Treatment Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 135. WinSanTor Chemotherapy Induced Peripheral Neuropathy Treatment Product Portfolio Table 136. WinSanTor Recent Development Table 137. Key Raw Materials Table 138. Raw Materials Key Suppliers Table 139. Chemotherapy Induced Peripheral Neuropathy Treatment Distributors List Table 140. Chemotherapy Induced Peripheral Neuropathy Treatment Customers List Table 141. Research Programs/Design for This Report Table 142. Authors List of This Report Table 143. Secondary Sources Table 144. Primary Sources List of Figures Figure 1. Chemotherapy Induced Peripheral Neuropathy Treatment Product Image Figure 2. Global Chemotherapy Induced Peripheral Neuropathy Treatment Sales Value (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Chemotherapy Induced Peripheral Neuropathy Treatment Sales Value (2021-2032) & (US$ Million) Figure 4. Global Chemotherapy Induced Peripheral Neuropathy Treatment Sales (2021-2032) & (K Units) Figure 5. Global Chemotherapy Induced Peripheral Neuropathy Treatment Sales Average Price (US$/Unit) & (2021-2032) Figure 6. Global Chemotherapy Induced Peripheral Neuropathy Treatment Company Revenue Ranking in 2025 (US$ Million) Figure 7. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 8. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 9. Calcium Channel α2-delta Ligands Image Figure 10. Antidepressants Image Figure 11. Opioids Image Figure 12. Others Image Figure 13. Global Chemotherapy Induced Peripheral Neuropathy Treatment Sales Volume by Type (2021 VS 2025 VS 2032) & (K Units) Figure 14. Global Chemotherapy Induced Peripheral Neuropathy Treatment Sales Volume Share 2021 VS 2025 VS 2032 Figure 15. Global Chemotherapy Induced Peripheral Neuropathy Treatment Sales Volume Share by Type (2021-2032) Figure 16. Global Chemotherapy Induced Peripheral Neuropathy Treatment Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 17. Global Chemotherapy Induced Peripheral Neuropathy Treatment Sales Value Share 2021 VS 2025 VS 2032 Figure 18. Global Chemotherapy Induced Peripheral Neuropathy Treatment Sales Value Share by Type (2021-2032) Figure 19. Platinum Agents Image Figure 20. Taxanes Image Figure 21. Vinca Alkaloids Image Figure 22. Others Image Figure 23. Global Chemotherapy Induced Peripheral Neuropathy Treatment Sales Volume by Application (2021 VS 2025 VS 2032) & (K Units) Figure 24. Global Chemotherapy Induced Peripheral Neuropathy Treatment Sales Volume Share 2021 VS 2025 VS 2032 Figure 25. Global Chemotherapy Induced Peripheral Neuropathy Treatment Sales Volume Share by Application (2021-2032) Figure 26. Global Chemotherapy Induced Peripheral Neuropathy Treatment Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 27. Global Chemotherapy Induced Peripheral Neuropathy Treatment Sales Value Share 2021 VS 2025 VS 2032 Figure 28. Global Chemotherapy Induced Peripheral Neuropathy Treatment Sales Value Share by Application (2021-2032) Figure 29. Global Chemotherapy Induced Peripheral Neuropathy Treatment Sales by Region: 2021 VS 2025 VS 2032 (K Units) Figure 30. Global Chemotherapy Induced Peripheral Neuropathy Treatment Sales Market Share by Region: 2021 VS 2025 VS 2032 Figure 31. Global Chemotherapy Induced Peripheral Neuropathy Treatment Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 32. Global Chemotherapy Induced Peripheral Neuropathy Treatment Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 33. North America Chemotherapy Induced Peripheral Neuropathy Treatment Sales Value (2021-2032) & (US$ Million) Figure 34. North America Chemotherapy Induced Peripheral Neuropathy Treatment Sales Value Share by Country (%), 2025 VS 2032 Figure 35. Europe Chemotherapy Induced Peripheral Neuropathy Treatment Sales Value (2021-2032) & (US$ Million) Figure 36. Europe Chemotherapy Induced Peripheral Neuropathy Treatment Sales Value Share by Country (%), 2025 VS 2032 Figure 37. Asia-Pacific Chemotherapy Induced Peripheral Neuropathy Treatment Sales Value (2021-2032) & (US$ Million) Figure 38. Asia-Pacific Chemotherapy Induced Peripheral Neuropathy Treatment Sales Value Share by Country (%), 2025 VS 2032 Figure 39. South America Chemotherapy Induced Peripheral Neuropathy Treatment Sales Value (2021-2032) & (US$ Million) Figure 40. South America Chemotherapy Induced Peripheral Neuropathy Treatment Sales Value Share by Country (%), 2025 VS 2032 Figure 41. Middle East & Africa Chemotherapy Induced Peripheral Neuropathy Treatment Sales Value (2021-2032) & (US$ Million) Figure 42. Middle East & Africa Chemotherapy Induced Peripheral Neuropathy Treatment Sales Value Share by Country (%), 2025 VS 2032 Figure 43. USA Chemotherapy Induced Peripheral Neuropathy Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 44. USA Chemotherapy Induced Peripheral Neuropathy Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 45. USA Chemotherapy Induced Peripheral Neuropathy Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 46. Canada Chemotherapy Induced Peripheral Neuropathy Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 47. Canada Chemotherapy Induced Peripheral Neuropathy Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 48. Canada Chemotherapy Induced Peripheral Neuropathy Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 49. Mexico Chemotherapy Induced Peripheral Neuropathy Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 50. Mexico Chemotherapy Induced Peripheral Neuropathy Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 51. Mexico Chemotherapy Induced Peripheral Neuropathy Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 52. Germany Chemotherapy Induced Peripheral Neuropathy Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 53. Germany Chemotherapy Induced Peripheral Neuropathy Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 54. Germany Chemotherapy Induced Peripheral Neuropathy Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 55. France Chemotherapy Induced Peripheral Neuropathy Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 56. France Chemotherapy Induced Peripheral Neuropathy Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 57. France Chemotherapy Induced Peripheral Neuropathy Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 58. U.K. Chemotherapy Induced Peripheral Neuropathy Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 59. U.K. Chemotherapy Induced Peripheral Neuropathy Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 60. U.K. Chemotherapy Induced Peripheral Neuropathy Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 61. Italy Chemotherapy Induced Peripheral Neuropathy Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 62. Italy Chemotherapy Induced Peripheral Neuropathy Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 63. Italy Chemotherapy Induced Peripheral Neuropathy Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 64. Spain Chemotherapy Induced Peripheral Neuropathy Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 65. Spain Chemotherapy Induced Peripheral Neuropathy Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 66. Spain Chemotherapy Induced Peripheral Neuropathy Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 67. Russia Chemotherapy Induced Peripheral Neuropathy Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 68. Russia Chemotherapy Induced Peripheral Neuropathy Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 69. Russia Chemotherapy Induced Peripheral Neuropathy Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 70. Netherlands Chemotherapy Induced Peripheral Neuropathy Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 71. Netherlands Chemotherapy Induced Peripheral Neuropathy Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 72. Netherlands Chemotherapy Induced Peripheral Neuropathy Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 73. Nordic Countries Chemotherapy Induced Peripheral Neuropathy Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 74. Nordic Countries Chemotherapy Induced Peripheral Neuropathy Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 75. Nordic Countries Chemotherapy Induced Peripheral Neuropathy Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 76. China Chemotherapy Induced Peripheral Neuropathy Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 77. China Chemotherapy Induced Peripheral Neuropathy Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 78. China Chemotherapy Induced Peripheral Neuropathy Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 79. Japan Chemotherapy Induced Peripheral Neuropathy Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 80. Japan Chemotherapy Induced Peripheral Neuropathy Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 81. Japan Chemotherapy Induced Peripheral Neuropathy Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 82. South Korea Chemotherapy Induced Peripheral Neuropathy Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 83. South Korea Chemotherapy Induced Peripheral Neuropathy Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 84. South Korea Chemotherapy Induced Peripheral Neuropathy Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 85. India Chemotherapy Induced Peripheral Neuropathy Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 86. India Chemotherapy Induced Peripheral Neuropathy Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 87. India Chemotherapy Induced Peripheral Neuropathy Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 88. Australia Chemotherapy Induced Peripheral Neuropathy Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 89. Australia Chemotherapy Induced Peripheral Neuropathy Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 90. Australia Chemotherapy Induced Peripheral Neuropathy Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 91. Southeast Asia Chemotherapy Induced Peripheral Neuropathy Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 92. Southeast Asia Chemotherapy Induced Peripheral Neuropathy Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 93. Southeast Asia Chemotherapy Induced Peripheral Neuropathy Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 94. Brazil Chemotherapy Induced Peripheral Neuropathy Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 95. Brazil Chemotherapy Induced Peripheral Neuropathy Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 96. Brazil Chemotherapy Induced Peripheral Neuropathy Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 97. Argentina Chemotherapy Induced Peripheral Neuropathy Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 98. Argentina Chemotherapy Induced Peripheral Neuropathy Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 99. Argentina Chemotherapy Induced Peripheral Neuropathy Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 100. Chile Chemotherapy Induced Peripheral Neuropathy Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 101. Chile Chemotherapy Induced Peripheral Neuropathy Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 102. Chile Chemotherapy Induced Peripheral Neuropathy Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 103. Colombia Chemotherapy Induced Peripheral Neuropathy Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 104. Colombia Chemotherapy Induced Peripheral Neuropathy Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 105. Colombia Chemotherapy Induced Peripheral Neuropathy Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 106. Peru Chemotherapy Induced Peripheral Neuropathy Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 107. Peru Chemotherapy Induced Peripheral Neuropathy Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 108. Peru Chemotherapy Induced Peripheral Neuropathy Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 109. Saudi Arabia Chemotherapy Induced Peripheral Neuropathy Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 110. Saudi Arabia Chemotherapy Induced Peripheral Neuropathy Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 111. Saudi Arabia Chemotherapy Induced Peripheral Neuropathy Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 112. Israel Chemotherapy Induced Peripheral Neuropathy Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 113. Israel Arabia Chemotherapy Induced Peripheral Neuropathy Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 114. Israel Arabia Chemotherapy Induced Peripheral Neuropathy Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 115. UAE Chemotherapy Induced Peripheral Neuropathy Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 116. UAE Chemotherapy Induced Peripheral Neuropathy Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 117. UAE Chemotherapy Induced Peripheral Neuropathy Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 118. Turkey Chemotherapy Induced Peripheral Neuropathy Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 119. Turkey Chemotherapy Induced Peripheral Neuropathy Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 120. Turkey Chemotherapy Induced Peripheral Neuropathy Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 121. Iran Chemotherapy Induced Peripheral Neuropathy Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 122. Iran Chemotherapy Induced Peripheral Neuropathy Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 123. Iran Chemotherapy Induced Peripheral Neuropathy Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 124. Egypt Chemotherapy Induced Peripheral Neuropathy Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 125. Egypt Chemotherapy Induced Peripheral Neuropathy Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 126. Egypt Chemotherapy Induced Peripheral Neuropathy Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 127. Chemotherapy Induced Peripheral Neuropathy Treatment Value Chain Figure 128. Manufacturing Cost Structure Figure 129. Chemotherapy Induced Peripheral Neuropathy Treatment Sales Mode & Process Figure 130. Direct Comparison with Distribution Share Figure 131. Distributors Profiles Figure 132. Years Considered Figure 133. Research Process Figure 134. Key Executives Interviewed

Scope & coverage.

Types
  • Calcium Channel α2-delta Ligands
  • Antidepressants
  • Opioids
  • Others
Applications
  • Platinum Agents
  • Taxanes
  • Vinca Alkaloids
  • Others
Companies covered
  • Aptinyx Inc
  • Asahi Kasei Pharma Corp
  • Regenacy Pharmaceuticals
  • MAKScientific LLC
  • Metys Pharmaceuticals AG
  • Nemus Bioscience Inc
  • PledPharma
  • Sova Pharmaceuticals Inc
  • DermaXon LLC
  • Kineta Inc
  • Krenitsky Pharmaceuticals Inc
  • PeriphaGen
  • Apexian Pharma
  • WinSanTor

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global Chemotherapy Induced Peripheral Neuropathy Treatment Sales Value (2021-2032)
  4. 1.2.2 Global Chemotherapy Induced Peripheral Neuropathy Treatment Sales Volume (2021-2032)
  5. 1.2.3 Global Chemotherapy Induced Peripheral Neuropathy Treatment Sales Average Price (2021-2032)
  6. 1.3 Assumptions and Limitations
  7. 1.4 Study Goals and Objectives
2 Chemotherapy Induced Peripheral Neuropathy Treatment Market Dynamics
  1. 2.1 Chemotherapy Induced Peripheral Neuropathy Treatment Industry Trends
  2. 2.2 Chemotherapy Induced Peripheral Neuropathy Treatment Industry Drivers
  3. 2.3 Chemotherapy Induced Peripheral Neuropathy Treatment Industry Opportunities and Challenges
  4. 2.4 Chemotherapy Induced Peripheral Neuropathy Treatment Industry Restraints
3 Chemotherapy Induced Peripheral Neuropathy Treatment Market by Company
  1. 3.1 Global Chemotherapy Induced Peripheral Neuropathy Treatment Company Revenue Ranking in 2025
  2. 3.2 Global Chemotherapy Induced Peripheral Neuropathy Treatment Revenue by Company (2021-2026)
  3. 3.3 Global Chemotherapy Induced Peripheral Neuropathy Treatment Sales Volume by Company (2021-2026)
  4. 3.4 Global Chemotherapy Induced Peripheral Neuropathy Treatment Average Price by Company (2021-2026)
  5. 3.5 Global Chemotherapy Induced Peripheral Neuropathy Treatment Company Ranking (2024-2026)
  6. 3.6 Global Chemotherapy Induced Peripheral Neuropathy Treatment Company Manufacturing Base and Headquarters
  7. 3.7 Global Chemotherapy Induced Peripheral Neuropathy Treatment Company Product Type and Application
  8. 3.8 Global Chemotherapy Induced Peripheral Neuropathy Treatment Company Establishment Date
  9. 3.9 Market Competitive Analysis
  10. 3.9.1 Global Chemotherapy Induced Peripheral Neuropathy Treatment Market Concentration Ratio (CR5 and HHI)
  11. 3.9.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  12. 3.9.3 2025 Chemotherapy Induced Peripheral Neuropathy Treatment Tier 1, Tier 2, and Tier 3 Companies
  13. 3.10 Mergers and Acquisitions Expansion
4 Chemotherapy Induced Peripheral Neuropathy Treatment Market by Type
  1. 4.1 Chemotherapy Induced Peripheral Neuropathy Treatment Type Introduction
  2. 4.1.1 Calcium Channel α2-delta Ligands
  3. 4.1.2 Antidepressants
  4. 4.1.3 Opioids
  5. 4.1.4 Others
  6. 4.2 Global Chemotherapy Induced Peripheral Neuropathy Treatment Sales Volume by Type
  7. 4.2.1 Global Chemotherapy Induced Peripheral Neuropathy Treatment Sales Volume by Type (2021 VS 2025 VS 2032)
  8. 4.2.2 Global Chemotherapy Induced Peripheral Neuropathy Treatment Sales Volume by Type (2021-2032)
  9. 4.2.3 Global Chemotherapy Induced Peripheral Neuropathy Treatment Sales Volume Share by Type (2021-2032)
  10. 4.3 Global Chemotherapy Induced Peripheral Neuropathy Treatment Sales Value by Type
  11. 4.3.1 Global Chemotherapy Induced Peripheral Neuropathy Treatment Sales Value by Type (2021 VS 2025 VS 2032)
  12. 4.3.2 Global Chemotherapy Induced Peripheral Neuropathy Treatment Sales Value by Type (2021-2032)
  13. 4.3.3 Global Chemotherapy Induced Peripheral Neuropathy Treatment Sales Value Share by Type (2021-2032)
5 Chemotherapy Induced Peripheral Neuropathy Treatment Market by Application
  1. 5.1 Chemotherapy Induced Peripheral Neuropathy Treatment Application Introduction
  2. 5.1.1 Platinum Agents
  3. 5.1.2 Taxanes
  4. 5.1.3 Vinca Alkaloids
  5. 5.1.4 Others
  6. 5.2 Global Chemotherapy Induced Peripheral Neuropathy Treatment Sales Volume by Application
  7. 5.2.1 Global Chemotherapy Induced Peripheral Neuropathy Treatment Sales Volume by Application (2021 VS 2025 VS 2032)
  8. 5.2.2 Global Chemotherapy Induced Peripheral Neuropathy Treatment Sales Volume by Application (2021-2032)
  9. 5.2.3 Global Chemotherapy Induced Peripheral Neuropathy Treatment Sales Volume Share by Application (2021-2032)
  10. 5.3 Global Chemotherapy Induced Peripheral Neuropathy Treatment Sales Value by Application
  11. 5.3.1 Global Chemotherapy Induced Peripheral Neuropathy Treatment Sales Value by Application (2021 VS 2025 VS 2032)
  12. 5.3.2 Global Chemotherapy Induced Peripheral Neuropathy Treatment Sales Value by Application (2021-2032)
  13. 5.3.3 Global Chemotherapy Induced Peripheral Neuropathy Treatment Sales Value Share by Application (2021-2032)
6 Chemotherapy Induced Peripheral Neuropathy Treatment Regional Sales and Value Analysis
  1. 6.1 Global Chemotherapy Induced Peripheral Neuropathy Treatment Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Chemotherapy Induced Peripheral Neuropathy Treatment Sales by Region (2021-2032)
  3. 6.2.1 Global Chemotherapy Induced Peripheral Neuropathy Treatment Sales by Region: 2021-2026
  4. 6.2.2 Global Chemotherapy Induced Peripheral Neuropathy Treatment Sales by Region (2027-2032)
  5. 6.3 Global Chemotherapy Induced Peripheral Neuropathy Treatment Sales Value by Region: 2021 VS 2025 VS 2032
  6. 6.4 Global Chemotherapy Induced Peripheral Neuropathy Treatment Sales Value by Region (2021-2032)
  7. 6.4.1 Global Chemotherapy Induced Peripheral Neuropathy Treatment Sales Value by Region: 2021-2026
  8. 6.4.2 Global Chemotherapy Induced Peripheral Neuropathy Treatment Sales Value by Region (2027-2032)
  9. 6.5 Global Chemotherapy Induced Peripheral Neuropathy Treatment Market Price Analysis by Region (2021-2026)
  10. 6.6 North America
  11. 6.6.1 North America Chemotherapy Induced Peripheral Neuropathy Treatment Sales Value (2021-2032)
  12. 6.6.2 North America Chemotherapy Induced Peripheral Neuropathy Treatment Sales Value Share by Country, 2025 VS 2032
  13. 6.7 Europe
  14. 6.7.1 Europe Chemotherapy Induced Peripheral Neuropathy Treatment Sales Value (2021-2032)
  15. 6.7.2 Europe Chemotherapy Induced Peripheral Neuropathy Treatment Sales Value Share by Country, 2025 VS 2032
  16. 6.8 Asia-Pacific
  17. 6.8.1 Asia-Pacific Chemotherapy Induced Peripheral Neuropathy Treatment Sales Value (2021-2032)
  18. 6.8.2 Asia-Pacific Chemotherapy Induced Peripheral Neuropathy Treatment Sales Value Share by Country, 2025 VS 2032
  19. 6.9 South America
  20. 6.9.1 South America Chemotherapy Induced Peripheral Neuropathy Treatment Sales Value (2021-2032)
  21. 6.9.2 South America Chemotherapy Induced Peripheral Neuropathy Treatment Sales Value Share by Country, 2025 VS 2032
  22. 6.10 Middle East & Africa
  23. 6.10.1 Middle East & Africa Chemotherapy Induced Peripheral Neuropathy Treatment Sales Value (2021-2032)
  24. 6.10.2 Middle East & Africa Chemotherapy Induced Peripheral Neuropathy Treatment Sales Value Share by Country, 2025 VS 2032
7 Chemotherapy Induced Peripheral Neuropathy Treatment Country-level Sales and Value Analysis
  1. 7.1 Global Chemotherapy Induced Peripheral Neuropathy Treatment Sales by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Chemotherapy Induced Peripheral Neuropathy Treatment Sales Value by Country: 2021 VS 2025 VS 2032
  3. 7.3 Global Chemotherapy Induced Peripheral Neuropathy Treatment Sales by Country (2021-2032)
  4. 7.3.1 Global Chemotherapy Induced Peripheral Neuropathy Treatment Sales by Country (2021-2026)
  5. 7.3.2 Global Chemotherapy Induced Peripheral Neuropathy Treatment Sales by Country (2027-2032)
  6. 7.4 Global Chemotherapy Induced Peripheral Neuropathy Treatment Sales Value by Country (2021-2032)
  7. 7.4.1 Global Chemotherapy Induced Peripheral Neuropathy Treatment Sales Value by Country (2021-2026)
  8. 7.4.2 Global Chemotherapy Induced Peripheral Neuropathy Treatment Sales Value by Country (2027-2032)
  9. 7.5 USA
  10. 7.5.1 USA Chemotherapy Induced Peripheral Neuropathy Treatment Sales Value Growth Rate (2021-2032)
  11. 7.5.2 USA Chemotherapy Induced Peripheral Neuropathy Treatment Sales Value Share by Type, 2025 VS 2032
  12. 7.5.3 USA Chemotherapy Induced Peripheral Neuropathy Treatment Sales Value Share by Application, 2025 VS 2032
  13. 7.6 Canada
  14. 7.6.1 Canada Chemotherapy Induced Peripheral Neuropathy Treatment Sales Value Growth Rate (2021-2032)
  15. 7.6.2 Canada Chemotherapy Induced Peripheral Neuropathy Treatment Sales Value Share by Type, 2025 VS 2032
  16. 7.6.3 Canada Chemotherapy Induced Peripheral Neuropathy Treatment Sales Value Share by Application, 2025 VS 2032
  17. 7.7 Mexico
  18. 7.6.1 Mexico Chemotherapy Induced Peripheral Neuropathy Treatment Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Mexico Chemotherapy Induced Peripheral Neuropathy Treatment Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Mexico Chemotherapy Induced Peripheral Neuropathy Treatment Sales Value Share by Application, 2025 VS 2032
  21. 7.8 Germany
  22. 7.8.1 Germany Chemotherapy Induced Peripheral Neuropathy Treatment Sales Value Growth Rate (2021-2032)
  23. 7.8.2 Germany Chemotherapy Induced Peripheral Neuropathy Treatment Sales Value Share by Type, 2025 VS 2032
  24. 7.8.3 Germany Chemotherapy Induced Peripheral Neuropathy Treatment Sales Value Share by Application, 2025 VS 2032
  25. 7.9 France
  26. 7.9.1 France Chemotherapy Induced Peripheral Neuropathy Treatment Sales Value Growth Rate (2021-2032)
  27. 7.9.2 France Chemotherapy Induced Peripheral Neuropathy Treatment Sales Value Share by Type, 2025 VS 2032
  28. 7.9.3 France Chemotherapy Induced Peripheral Neuropathy Treatment Sales Value Share by Application, 2025 VS 2032
  29. 7.10 U.K.
  30. 7.10.1 U.K. Chemotherapy Induced Peripheral Neuropathy Treatment Sales Value Growth Rate (2021-2032)
  31. 7.10.2 U.K. Chemotherapy Induced Peripheral Neuropathy Treatment Sales Value Share by Type, 2025 VS 2032
  32. 7.10.3 U.K. Chemotherapy Induced Peripheral Neuropathy Treatment Sales Value Share by Application, 2025 VS 2032
  33. 7.11 Italy
  34. 7.11.1 Italy Chemotherapy Induced Peripheral Neuropathy Treatment Sales Value Growth Rate (2021-2032)
  35. 7.11.2 Italy Chemotherapy Induced Peripheral Neuropathy Treatment Sales Value Share by Type, 2025 VS 2032
  36. 7.11.3 Italy Chemotherapy Induced Peripheral Neuropathy Treatment Sales Value Share by Application, 2025 VS 2032
  37. 7.12 Spain
  38. 7.12.1 Spain Chemotherapy Induced Peripheral Neuropathy Treatment Sales Value Growth Rate (2021-2032)
  39. 7.12.2 Spain Chemotherapy Induced Peripheral Neuropathy Treatment Sales Value Share by Type, 2025 VS 2032
  40. 7.12.3 Spain Chemotherapy Induced Peripheral Neuropathy Treatment Sales Value Share by Application, 2025 VS 2032
  41. 7.13 Russia
  42. 7.13.1 Russia Chemotherapy Induced Peripheral Neuropathy Treatment Sales Value Growth Rate (2021-2032)
  43. 7.13.2 Russia Chemotherapy Induced Peripheral Neuropathy Treatment Sales Value Share by Type, 2025 VS 2032
  44. 7.13.3 Russia Chemotherapy Induced Peripheral Neuropathy Treatment Sales Value Share by Application, 2025 VS 2032
  45. 7.14 Netherlands
  46. 7.14.1 Netherlands Chemotherapy Induced Peripheral Neuropathy Treatment Sales Value Growth Rate (2021-2032)
  47. 7.14.2 Netherlands Chemotherapy Induced Peripheral Neuropathy Treatment Sales Value Share by Type, 2025 VS 2032
  48. 7.14.3 Netherlands Chemotherapy Induced Peripheral Neuropathy Treatment Sales Value Share by Application, 2025 VS 2032
  49. 7.15 Nordic Countries
  50. 7.15.1 Nordic Countries Chemotherapy Induced Peripheral Neuropathy Treatment Sales Value Growth Rate (2021-2032)
  51. 7.15.2 Nordic Countries Chemotherapy Induced Peripheral Neuropathy Treatment Sales Value Share by Type, 2025 VS 2032
  52. 7.15.3 Nordic Countries Chemotherapy Induced Peripheral Neuropathy Treatment Sales Value Share by Application, 2025 VS 2032
  53. 7.16 China
  54. 7.16.1 China Chemotherapy Induced Peripheral Neuropathy Treatment Sales Value Growth Rate (2021-2032)
  55. 7.16.2 China Chemotherapy Induced Peripheral Neuropathy Treatment Sales Value Share by Type, 2025 VS 2032
  56. 7.16.3 China Chemotherapy Induced Peripheral Neuropathy Treatment Sales Value Share by Application, 2025 VS 2032
  57. 7.17 Japan
  58. 7.17.1 Japan Chemotherapy Induced Peripheral Neuropathy Treatment Sales Value Growth Rate (2021-2032)
  59. 7.17.2 Japan Chemotherapy Induced Peripheral Neuropathy Treatment Sales Value Share by Type, 2025 VS 2032
  60. 7.17.3 Japan Chemotherapy Induced Peripheral Neuropathy Treatment Sales Value Share by Application, 2025 VS 2032
  61. 7.18 South Korea
  62. 7.18.1 South Korea Chemotherapy Induced Peripheral Neuropathy Treatment Sales Value Growth Rate (2021-2032)
  63. 7.18.2 South Korea Chemotherapy Induced Peripheral Neuropathy Treatment Sales Value Share by Type, 2025 VS 2032
  64. 7.18.3 South Korea Chemotherapy Induced Peripheral Neuropathy Treatment Sales Value Share by Application, 2025 VS 2032
  65. 7.19 India
  66. 7.19.1 India Chemotherapy Induced Peripheral Neuropathy Treatment Sales Value Growth Rate (2021-2032)
  67. 7.19.2 India Chemotherapy Induced Peripheral Neuropathy Treatment Sales Value Share by Type, 2025 VS 2032
  68. 7.19.3 India Chemotherapy Induced Peripheral Neuropathy Treatment Sales Value Share by Application, 2025 VS 2032
  69. 7.20 Australia
  70. 7.20.1 Australia Chemotherapy Induced Peripheral Neuropathy Treatment Sales Value Growth Rate (2021-2032)
  71. 7.20.2 Australia Chemotherapy Induced Peripheral Neuropathy Treatment Sales Value Share by Type, 2025 VS 2032
  72. 7.20.3 Australia Chemotherapy Induced Peripheral Neuropathy Treatment Sales Value Share by Application, 2025 VS 2032
  73. 7.21 Southeast Asia
  74. 7.21.1 Southeast Asia Chemotherapy Induced Peripheral Neuropathy Treatment Sales Value Growth Rate (2021-2032)
  75. 7.21.2 Southeast Asia Chemotherapy Induced Peripheral Neuropathy Treatment Sales Value Share by Type, 2025 VS 2032
  76. 7.21.3 Southeast Asia Chemotherapy Induced Peripheral Neuropathy Treatment Sales Value Share by Application, 2025 VS 2032
  77. 7.22 Brazil
  78. 7.22.1 Brazil Chemotherapy Induced Peripheral Neuropathy Treatment Sales Value Growth Rate (2021-2032)
  79. 7.22.2 Brazil Chemotherapy Induced Peripheral Neuropathy Treatment Sales Value Share by Type, 2025 VS 2032
  80. 7.22.3 Brazil Chemotherapy Induced Peripheral Neuropathy Treatment Sales Value Share by Application, 2025 VS 2032
  81. 7.23 Argentina
  82. 7.23.1 Argentina Chemotherapy Induced Peripheral Neuropathy Treatment Sales Value Growth Rate (2021-2032)
  83. 7.23.2 Argentina Chemotherapy Induced Peripheral Neuropathy Treatment Sales Value Share by Type, 2025 VS 2032
  84. 7.23.3 Argentina Chemotherapy Induced Peripheral Neuropathy Treatment Sales Value Share by Application, 2025 VS 2032
  85. 7.24 Chile
  86. 7.24.1 Chile Chemotherapy Induced Peripheral Neuropathy Treatment Sales Value Growth Rate (2021-2032)
  87. 7.24.2 Chile Chemotherapy Induced Peripheral Neuropathy Treatment Sales Value Share by Type, 2025 VS 2032
  88. 7.24.3 Chile Chemotherapy Induced Peripheral Neuropathy Treatment Sales Value Share by Application, 2025 VS 2032
  89. 7.25 Colombia
  90. 7.25.1 Colombia Chemotherapy Induced Peripheral Neuropathy Treatment Sales Value Growth Rate (2021-2032)
  91. 7.25.2 Colombia Chemotherapy Induced Peripheral Neuropathy Treatment Sales Value Share by Type, 2025 VS 2032
  92. 7.25.3 Colombia Chemotherapy Induced Peripheral Neuropathy Treatment Sales Value Share by Application, 2025 VS 2032
  93. 7.26 Peru
  94. 7.26.1 Peru Chemotherapy Induced Peripheral Neuropathy Treatment Sales Value Growth Rate (2021-2032)
  95. 7.26.2 Peru Chemotherapy Induced Peripheral Neuropathy Treatment Sales Value Share by Type, 2025 VS 2032
  96. 7.26.3 Peru Chemotherapy Induced Peripheral Neuropathy Treatment Sales Value Share by Application, 2025 VS 2032
  97. 7.27 Saudi Arabia
  98. 7.27.1 Saudi Arabia Chemotherapy Induced Peripheral Neuropathy Treatment Sales Value Growth Rate (2021-2032)
  99. 7.27.2 Saudi Arabia Chemotherapy Induced Peripheral Neuropathy Treatment Sales Value Share by Type, 2025 VS 2032
  100. 7.27.3 Saudi Arabia Chemotherapy Induced Peripheral Neuropathy Treatment Sales Value Share by Application, 2025 VS 2032
  101. 7.28 Israel
  102. 7.28.1 Israel Chemotherapy Induced Peripheral Neuropathy Treatment Sales Value Growth Rate (2021-2032)
  103. 7.28.2 Israel Chemotherapy Induced Peripheral Neuropathy Treatment Sales Value Share by Type, 2025 VS 2032
  104. 7.28.3 Israel Chemotherapy Induced Peripheral Neuropathy Treatment Sales Value Share by Application, 2025 VS 2032
  105. 7.29 UAE
  106. 7.29.1 UAE Chemotherapy Induced Peripheral Neuropathy Treatment Sales Value Growth Rate (2021-2032)
  107. 7.29.2 UAE Chemotherapy Induced Peripheral Neuropathy Treatment Sales Value Share by Type, 2025 VS 2032
  108. 7.29.3 UAE Chemotherapy Induced Peripheral Neuropathy Treatment Sales Value Share by Application, 2025 VS 2032
  109. 7.30 Turkey
  110. 7.30.1 Turkey Chemotherapy Induced Peripheral Neuropathy Treatment Sales Value Growth Rate (2021-2032)
  111. 7.30.2 Turkey Chemotherapy Induced Peripheral Neuropathy Treatment Sales Value Share by Type, 2025 VS 2032
  112. 7.30.3 Turkey Chemotherapy Induced Peripheral Neuropathy Treatment Sales Value Share by Application, 2025 VS 2032
  113. 7.31 Iran
  114. 7.31.1 Iran Chemotherapy Induced Peripheral Neuropathy Treatment Sales Value Growth Rate (2021-2032)
  115. 7.31.2 Iran Chemotherapy Induced Peripheral Neuropathy Treatment Sales Value Share by Type, 2025 VS 2032
  116. 7.31.3 Iran Chemotherapy Induced Peripheral Neuropathy Treatment Sales Value Share by Application, 2025 VS 2032
  117. 7.32 Egypt
  118. 7.32.1 Egypt Chemotherapy Induced Peripheral Neuropathy Treatment Sales Value Growth Rate (2021-2032)
  119. 7.32.2 Egypt Chemotherapy Induced Peripheral Neuropathy Treatment Sales Value Share by Type, 2025 VS 2032
  120. 7.32.3 Egypt Chemotherapy Induced Peripheral Neuropathy Treatment Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Aptinyx Inc
  2. 8.1.1 Aptinyx Inc Company Information
  3. 8.1.2 Aptinyx Inc Business Overview
  4. 8.1.3 Aptinyx Inc Chemotherapy Induced Peripheral Neuropathy Treatment Sales, Value and Gross Margin (2021-2026)
  5. 8.1.4 Aptinyx Inc Chemotherapy Induced Peripheral Neuropathy Treatment Product Portfolio
  6. 8.1.5 Aptinyx Inc Recent Developments
  7. 8.2 Asahi Kasei Pharma Corp
  8. 8.2.1 Asahi Kasei Pharma Corp Company Information
  9. 8.2.2 Asahi Kasei Pharma Corp Business Overview
  10. 8.2.3 Asahi Kasei Pharma Corp Chemotherapy Induced Peripheral Neuropathy Treatment Sales, Value and Gross Margin (2021-2026)
  11. 8.2.4 Asahi Kasei Pharma Corp Chemotherapy Induced Peripheral Neuropathy Treatment Product Portfolio
  12. 8.2.5 Asahi Kasei Pharma Corp Recent Developments
  13. 8.3 Regenacy Pharmaceuticals
  14. 8.3.1 Regenacy Pharmaceuticals Company Information
  15. 8.3.2 Regenacy Pharmaceuticals Business Overview
  16. 8.3.3 Regenacy Pharmaceuticals Chemotherapy Induced Peripheral Neuropathy Treatment Sales, Value and Gross Margin (2021-2026)
  17. 8.3.4 Regenacy Pharmaceuticals Chemotherapy Induced Peripheral Neuropathy Treatment Product Portfolio
  18. 8.3.5 Regenacy Pharmaceuticals Recent Developments
  19. 8.4 MAKScientific LLC
  20. 8.4.1 MAKScientific LLC Company Information
  21. 8.4.2 MAKScientific LLC Business Overview
  22. 8.4.3 MAKScientific LLC Chemotherapy Induced Peripheral Neuropathy Treatment Sales, Value and Gross Margin (2021-2026)
  23. 8.4.4 MAKScientific LLC Chemotherapy Induced Peripheral Neuropathy Treatment Product Portfolio
  24. 8.4.5 MAKScientific LLC Recent Developments
  25. 8.5 Metys Pharmaceuticals AG
  26. 8.5.1 Metys Pharmaceuticals AG Company Information
  27. 8.5.2 Metys Pharmaceuticals AG Business Overview
  28. 8.5.3 Metys Pharmaceuticals AG Chemotherapy Induced Peripheral Neuropathy Treatment Sales, Value and Gross Margin (2021-2026)
  29. 8.5.4 Metys Pharmaceuticals AG Chemotherapy Induced Peripheral Neuropathy Treatment Product Portfolio
  30. 8.5.5 Metys Pharmaceuticals AG Recent Developments
  31. 8.6 Nemus Bioscience Inc
  32. 8.6.1 Nemus Bioscience Inc Company Information
  33. 8.6.2 Nemus Bioscience Inc Business Overview
  34. 8.6.3 Nemus Bioscience Inc Chemotherapy Induced Peripheral Neuropathy Treatment Sales, Value and Gross Margin (2021-2026)
  35. 8.6.4 Nemus Bioscience Inc Chemotherapy Induced Peripheral Neuropathy Treatment Product Portfolio
  36. 8.6.5 Nemus Bioscience Inc Recent Developments
  37. 8.7 PledPharma
  38. 8.7.1 PledPharma Company Information
  39. 8.7.2 PledPharma Business Overview
  40. 8.7.3 PledPharma Chemotherapy Induced Peripheral Neuropathy Treatment Sales, Value and Gross Margin (2021-2026)
  41. 8.7.4 PledPharma Chemotherapy Induced Peripheral Neuropathy Treatment Product Portfolio
  42. 8.7.5 PledPharma Recent Developments
  43. 8.8 Sova Pharmaceuticals Inc
  44. 8.8.1 Sova Pharmaceuticals Inc Company Information
  45. 8.8.2 Sova Pharmaceuticals Inc Business Overview
  46. 8.8.3 Sova Pharmaceuticals Inc Chemotherapy Induced Peripheral Neuropathy Treatment Sales, Value and Gross Margin (2021-2026)
  47. 8.8.4 Sova Pharmaceuticals Inc Chemotherapy Induced Peripheral Neuropathy Treatment Product Portfolio
  48. 8.8.5 Sova Pharmaceuticals Inc Recent Developments
  49. 8.9 DermaXon LLC
  50. 8.9.1 DermaXon LLC Company Information
  51. 8.9.2 DermaXon LLC Business Overview
  52. 8.9.3 DermaXon LLC Chemotherapy Induced Peripheral Neuropathy Treatment Sales, Value and Gross Margin (2021-2026)
  53. 8.9.4 DermaXon LLC Chemotherapy Induced Peripheral Neuropathy Treatment Product Portfolio
  54. 8.9.5 DermaXon LLC Recent Developments
  55. 8.10 Kineta Inc
  56. 8.10.1 Kineta Inc Company Information
  57. 8.10.2 Kineta Inc Business Overview
  58. 8.10.3 Kineta Inc Chemotherapy Induced Peripheral Neuropathy Treatment Sales, Value and Gross Margin (2021-2026)
  59. 8.10.4 Kineta Inc Chemotherapy Induced Peripheral Neuropathy Treatment Product Portfolio
  60. 8.10.5 Kineta Inc Recent Developments
  61. 8.11 Krenitsky Pharmaceuticals Inc
  62. 8.11.1 Krenitsky Pharmaceuticals Inc Company Information
  63. 8.11.2 Krenitsky Pharmaceuticals Inc Business Overview
  64. 8.11.3 Krenitsky Pharmaceuticals Inc Chemotherapy Induced Peripheral Neuropathy Treatment Sales, Value and Gross Margin (2021-2026)
  65. 8.11.4 Krenitsky Pharmaceuticals Inc Chemotherapy Induced Peripheral Neuropathy Treatment Product Portfolio
  66. 8.11.5 Krenitsky Pharmaceuticals Inc Recent Developments
  67. 8.12 PeriphaGen
  68. 8.12.1 PeriphaGen Company Information
  69. 8.12.2 PeriphaGen Business Overview
  70. 8.12.3 PeriphaGen Chemotherapy Induced Peripheral Neuropathy Treatment Sales, Value and Gross Margin (2021-2026)
  71. 8.12.4 PeriphaGen Chemotherapy Induced Peripheral Neuropathy Treatment Product Portfolio
  72. 8.12.5 PeriphaGen Recent Developments
  73. 8.13 Apexian Pharma
  74. 8.13.1 Apexian Pharma Company Information
  75. 8.13.2 Apexian Pharma Business Overview
  76. 8.13.3 Apexian Pharma Chemotherapy Induced Peripheral Neuropathy Treatment Sales, Value and Gross Margin (2021-2026)
  77. 8.13.4 Apexian Pharma Chemotherapy Induced Peripheral Neuropathy Treatment Product Portfolio
  78. 8.13.5 Apexian Pharma Recent Developments
  79. 8.14 WinSanTor
  80. 8.14.1 WinSanTor Company Information
  81. 8.14.2 WinSanTor Business Overview
  82. 8.14.3 WinSanTor Chemotherapy Induced Peripheral Neuropathy Treatment Sales, Value and Gross Margin (2021-2026)
  83. 8.14.4 WinSanTor Chemotherapy Induced Peripheral Neuropathy Treatment Product Portfolio
  84. 8.14.5 WinSanTor Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Chemotherapy Induced Peripheral Neuropathy Treatment Value Chain Analysis
  2. 9.1.1 Chemotherapy Induced Peripheral Neuropathy Treatment Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Chemotherapy Induced Peripheral Neuropathy Treatment Sales Mode & Process
  6. 9.2 Chemotherapy Induced Peripheral Neuropathy Treatment Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Chemotherapy Induced Peripheral Neuropathy Treatment Distributors
  9. 9.2.3 Chemotherapy Induced Peripheral Neuropathy Treatment Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst